News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orexo AB Announces Decision to Explore Strategic Alternatives for Commercialization in the U.S.



10/4/2012 9:49:31 AM

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo (STO:ORX), a Swedish specialty pharmaceutical company with a focus on innovative sublingual drug delivery technologies, today announced that it has retained Guggenheim Securities, LLC as its financial advisor to assist in the Company’s review and evaluation of a full range of strategic alternatives. The Board of Directors initiated this review in conjunction with the Company’s ongoing evaluation of its US commercial plan, with the aim of enhancing both commercial prospects for the Company’s products and shareholder value.

Read at BioSpace.com


comments powered by Disqus
Orexo AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES